Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers

British Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2002, Pages 357-362

  Pecking, M ^a   Montestruc, F ^a   Marquet, P ^b   Wodey, E ^c   Homery, M C ^d   Dostert, P ^d  

^a Clinical Research Department   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d Biotrial SA   (France)

Author keywords

Bioavailability; Intravenous; Midazolam; Pharmacokinetics; Subcutaneous

Indexed keywords

DRUG METABOLITE; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BREATHING RATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INFUSION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; ERYTHEMA; HEADACHE; HEART FUNCTION; HEART PALPITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OXIMETRY; PAIN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANESTHETICS, INTRAVENOUS; BIOLOGICAL AVAILABILITY; CROSS-SECTIONAL STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDAZOLAM; TIME FACTORS;

EID: 0036431509     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01665.x     Document Type: Article

References (28)

1. Reves JG, Fragen J, Vinik H, Greenblatt J. Midazolam: Pharmacology and uses. Anesthesiol 1985;62: 310-324.
2. Drummond SH, Peterson GM, Galloway JG, Keefe PA. National survey of drug use in palliative care. Palliative Med 1996;10: 119-124.
3. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36: 89-96.
4. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human and cDNA-expressed human cytochrome P450. Drug Metab Dispos 1996;24: 940-947.
5. Bauer TM, Ritz R, Haberthür C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995;346: 145-147.
6. Smith MT, Eadie MJ, O'Rourke Brophy T. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981;19: 271-278.
7. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981;30: 653-661.
8. Clausen TG, Wolff J, Hansen PB, et al. Pharmacokinetics of midazolam anda-hydroxy-midazolam following rectal and intravenous administration. Br J Clin Pharmacol 1988; 25: 457-463.
9. Schwagmeier R, Alincic S, Striebel HW. Midazolam pharmacokinetics following intravenous and buccal administration. Br J Clin Pharmacol 1998;46: 203-206.
10. Björkman S, Rigemar G, Idvall J. Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. Br J Anaesth 1997;79: 575-580.
11. Crevoisier C, Eckert M, Heizmann P, Thurneysen DJ, Ziegler WH. Relation entre l'effet clinique et la pharmacocinétique du midazolam après administration i. v. et i m. Arzneim/Drug Res 1981;31: 2211-2215.
12. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983; (Suppl 1): 43S-49S.
13. Guengerich FP. Human cytochrome P450 enzymes. In Cytochrome P450 - Structure, Mechanism and Biochemistry, Ed. Ortiz de Montellano, PR. New York: Plenum Press, 1995: 473-535.
14. Platten H-P, Schweizer E, Dilger K, Mikus G, Klotz U. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther 1998;63: 552-560.
15. Geisslinger G, Dingemanse J, Schwilden H, Schüttler J. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999; 65: 630-639.
16. Greenblatt DJ, Abernathy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender and obesity on midazolam kinetics. Anesthesiol 1984;61: 27-35.
17. Oldenhof H, de Jong M, Steenhoek A, Janknegt R. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? Clin Pharmacol Ther 1988;43: 263-269.
18. Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: Application to midazolam. J Pharmacokinet Biopharm 1991;19: 377-384.
19. Johanson GA. Midazolam in terminal care. Am J Hospice Palliative Care 1993;10: 13-14.
20. Bleasel MD, Peterson GM, Dunne PF. Plasma concentrations of midazolam during continuous subcutaneous administration in palliative care. Palliative Med 1984;8: 231-236.
21. Marquet P, Baudin O, Gaulier JM, et al. Sensitive and specific determination of midazolam and 1-hydoxymidazolam in human serum by liquid chromatography-electrospray mass spectrometry. J Chromatogr B 1999;734: 137-144.
22. Machin D, Campbell M, Fayers P, Pinol A, eds.Sample Size Tables for Clinical Studies, 2nd Edn, Oxford: Blackwell Science, 1997: 131-142.
23. Benett J, Nichols F, Rosenblum M, Condry J. Subcutaneous administration of midazolam: A comparison of the Bioject Jet Injector with the conventional syringe and needle. J Oral Maxilofac Surg 1998;56: 1249-1254.
24. Fukuta O, Braham RL, Yanase H, Kurosu K. Intranasal administration of midazolam: Pharmacokinetic and pharmacodynamic properties and sedative potential. J Dent Child 1997;64: 89-98.
25. Burstein AH, Modica R, Hatton M, Forrest A, Gengo FM. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. J Clin Pharmacol 1997;37: 711-718.
26. Walberg EJ, Willis RJ, Eckhert J. Plasma concentrations of midazolam in children following intranasal administration. Anesthesiol 1991;74: 233-235.
27. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59: 491-502.
28. Klotz U, Ziegler G. Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther 1982; 32: 107-112.